Mechanism of action of vesicular monoamine transporter 2 (VMAT2) inhibitors in tardive dyskinesia: reducing dopamine leads to less “go” and more “stop” from the motor striatum for robust therapeutic effects
Author:
- Stephen M. StahlSSStephen M. Stahl
Open Access
- 18 December 2017
- journal article
- editorial
- Published by Cambridge University Press (CUP) in CNS Spectrums
- Vol. 23 (1) , 1-6
Abstract
Tardive dyskinesia can now be successfully treated by inhibiting the vesicular monoamine transporter type 2 (VMAT2).Keywords
This publication has 7 references indexed in Scilit:
- Neuronal traffic signals in tardive dyskinesia: not enough “stop” in the motor striatumCNS Spectrums, 2017
- Drugs for psychosis and mood: unique actions at D3, D2, and D1 dopamine receptor subtypesCNS Spectrums, 2017
- Dazzled by the dominions of dopamine: clinical roles of D3, D2, and D1 receptorsCNS Spectrums, 2017
- Randomized controlled trial of deutetrabenazine for tardive dyskinesiaNeurology, 2017
- KINECT 3: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Valbenazine for Tardive DyskinesiaAmerican Journal of Psychiatry, 2017
- Dopamine depleters in the treatment of hyperkinetic movement disordersExpert Opinion on Pharmacotherapy, 2016
- SLC18: Vesicular neurotransmitter transporters for monoamines and acetylcholineMolecular Aspects of Medicine, 2013